Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free

Flow Cytometry: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441]

Flow Cytometry: Ly-6G/Ly-6C Antibody (RB6-8C5) [NBP2-00441] - Analysis using the Allophycocyanin conjugate of NBP2-00441. Staining of C57BL/6 bone marrow cells with 0.125 ug of Rat IgG2b kappa Isotype Control APC (blue histogram) or 0.125 ug of Anti-Mouse Ly-6G (Gr-1) APC (purple histogram).

Immunohistochemistry-Paraffin: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441]

Immunohistochemistry-Paraffin: Ly-6G/Ly-6C Antibody (RB6-8C5) [NBP2-00441] - Analysis of a FFPE tissue section of mouse bone marrow using 1:100 dilution of Lot E04586-1632 of Ly-6G antibody (clone RB6-8C5). The antibody generated specific staining in a subset of cells in the tested section.

Immunohistochemistry-Paraffin: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441]

Immunohistochemistry-Paraffin: Ly-6G/Ly-6C Antibody (RB6-8C5) [NBP2-00441] - Analysis of a FFPE tissue section of mouse bone marrow using 1:200 dilution of Lot A-1 of Ly-6G antibody (clone RB6-8C5). The antibody generated specific staining in a subset of cells in the tested section. The neutrophils (identifiable from typical nuclear morphology) showed stronger signal than the neighboring cells.

Flow Cytometry: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441]

Flow Cytometry: Ly-6G/Ly-6C Antibody (RB6-8C5) [NBP2-00441] - Staining of mouse bone marrow with Anti-Mouse Ly-6G (Gr-1) FITC and Anti-Human/Mouse CD45R (B220) PE. Total viable cells were used for analysis.

Immunocytochemistry/ Immunofluorescence: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441] -

ICM and TE progenitors show loss of responsiveness to Hippo signaling manipulation at the same time as they loose responsiveness to positional changes.(A) Overview of Hippo signaling activation time course. Each bar represents 24 hr of 50 µM ROCKi treatment. (B) Percent of Cdx2 positive cells per embryo cultured for 24 hr in control or ROCKi conditions. Label on top indicates the stage embryos started treatment. n indicates number of embryos analyzed. Statistical significance was calculated using t-test and significant p-values are indicated. Error bars: s.d. of mean. (C) Strategy for inducible Hippo signaling inactivation. Mostly mosaic Dox-inducible DN Lats2-IRES-mCherry transgenic embryos were generated. Each bar represents 24 hr of Dox treatment. (D) Dox-inducible DN Lats2-IRES-mCherry transgenic embryos were imaged before Dox treatment (top panel) and the same embryo was imaged following 24 hr of Dox live (middle panel) and fixed/stained for lineage markers (bottom panel). A representative embryo is shown for each stage. Live mCherry is shown as an extended focus image, immunofluorescence stainings shown as single plane images. mCherry positive ICMs in mosaic transgenic embryos are circled with a dotted line. Arrow points to a rare ICM cell in a 64 cell stage-induced embryo with weak Cdx2 expression, which also co-expressed an ICM marker. Scale bar: 25 µm. n indicates number of transgenic embryos analyzed. (E) All mCherry negative (non-transgenic control) and mCherry positive (DN Lats2-mCherry transgenic) ICM cells were scored in mosaic embryos for presence or absence of lineage markers following 24 hr of Dox treatment by immunofluorescence staining. Cells with different lineage marker expression are shown as percent of all mCherry negative or mCherry positive ICM cells analyzed. n(cell) indicates number of cells analyzed at each stage and n(embryo) indicates number of embryos cells were pooled from. Chi-squared test was used to test whether cell fate was affected by DN Lats2-mCherry expression. 16 cell p-value=8.48491E-18; early 32 cell p-value=5.50841E-34; late 32 cell p-value=6.32116E-35; 64 cell p-value=0.004103716; >64 cell p-value=0.588416983.DOI:https://dx.doi.org/10.7554/eLife.22906.019Effect of ROCKi treatment on cell number and Hippo signaling.(A) Total cell numbers in control and 50 µM ROCKi treated embryos at different stages. n indicates number of embryos analyzed. Statistical significance was calculated using t-test and significant p-values are indicated. Error bars: s.d. of mean. (B) Immunofourescence staining of control and 50 µM ROCKi treated embryos for TE marker (Cdx2), ICM marker (Klf4) and Yap. 24 hr treatment was started at the 16 cell stage. A total of 4 control and 4 ROCKi-treated embryos were imaged in one experiment. Scale bar: 25 µm. (C) Immunofourescence staining of control and 50 µM ROCKi treated embryos for TE marker (Cdx2), ICM marker (Klf4) and phospho-Yap (form of Yap sequestered into the cytoplasm due to active Hippo signaling). 24 hr treatment was started at the 16 cell stage. A total of 4 control and 3 ROCKi-treated embryos were imaged in one experiment. Scale bar: 25 µm.DOI:https://dx.doi.org/10.7554/eLife.22906.020Expression of mCherry only does not influence cell fate in the embryo.2 cell stage embryos were injected with H2O (wild-type control) or a cocktail of PB-TAC-mCherry-IRES-mCherry, PB-CAG-rtTA and PBase mRNA (mCherry control). Embryos were treated with Dox for 24 hours starting at the 32 or 64 cell stages. Following Dox treatment cell fate of ICM cells was analyzed by immunofluorescence staining for lineage markers. Cell fates shown as percent of all H2O injected ICM cells (in H2O injected embryos) or all mCherry positive ICM cells (in mCherry control embryos). n(cell) indicates number of cells analyzed at each stage and n(embryo) indicates number of embryos cells were pooled from. Chi-squared test was used to test whether cell fate was affected by mCherry expression. 32 cell p-value= 0.139370244, 64 cell p-value= 0.07551351.DOI:https://dx.doi.org/10.7554/eLife.22906.021 Image collected and cropped by CiteAb from the following open publication (https://elifesciences.org/articles/22906), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441] -

Immunohistochemistry: Ly-6G/Ly-6C Antibody (RB6-8C5) - BSA Free [NBP2-00441] - Silencing lnc-Lfar1 alleviates CCl4-induced proinflammatory activation of macrophages.Mice were treated with oil in combination with injection of lenti-NC (NC, n = 10), CCl4 in combination with injection of lenti-NC (NC + CCl4, n = 10), oil in combination with injection of lenti-lnc-Lfar1-shRNA (lnc-Lfar1-shRNA, n = 10), & CCl4 in combination with injection of lenti-lnc-Lfar1-shRNA (lnc-Lfar1-shRNA + CCl4, n = 10). a Immunohistochemistry analysis was performed to detect the expression of F4/80 & LY6C; scale bar = 400 μm for 10 × and 100 μm for 40×. b The protein level of F4/80, CD11b & LY6C was determined by western blot. GAPDH was used as an internal control. c The mRNA level of F4/80, Ly6c, Ccr2, Cd20, Il-6, iNos, Ccl5, Cxcl5, Cxcl9 & Cxcl10 was determined by qRT-PCR. *p < 0.05 vs NC, #p < 0.05 vs NC + CCl4. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32071306), licensed under a CC-BY license. Not internally tested by Novus Biologicals.